Impact of Dnm3os silencing on bleomycin-induced lung fibrosis

To assess the impact of Dnm3os silencing on lung fibrogenesis, anti-Dnm3os gapmers (5mg/kg, 2 distinct designs: GP DNM3OS-1 and GP DNM3OS-3) or control gapmer (5mg/kg, GP Ctrl) formulated for in vivo delivery was instilled intratracheally 4 days and 2 days before intratracheal administration of bleomycin (1 unit/kg) or PBS as well as 4 days after bleomycin or PBS treatment. Experiments were performed in a one color design, corresponding to 6 conditions (GP Ctrl + PBS n = 3, GP DNM3OS-1 + PBS n = 3, GP DNM3OS-3 + PBS n = 3, GP Ctrl + Bleo n = 5, GP DNM3OS-1 + Bleo n = 5, GP DNM3OS-3 + Bleo n = 5) for a total of 24 samples.